Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Critical evaluation of drug response prediction models with DrEval.
PMID 42120410 · PMC13168506 · Nature communications · 2026 · 8 claims · 6 setups
DrEval is a living open-source benchmarking pipeline for unbiased, biologically meaningful evaluation of cancer drug response prediction models, integrating standardized preprocessing, hyperparameter tuning, statistically rigorous evaluation, cross-study benchmarks, and ablation studies.
-
Full-text index only
Multi-omics feature engineering driven by biomedical foundation models improves drug response prediction for inflammatory bowel disease patients.
PMID 41844950 · PMC13129071 · Scientific reports · 2026 · 8 claims · 7 setups
FM (MAMMAL)-derived drug-target binding affinity (BA) inference can be used to rank/select biologically relevant protein targets and their associated genes/SNPs for a drug of interest without knowledge of protein structure or active sites
-
Full-text index only
Radiogenomics predicts immune microenvironment heterogeneity and response to combination immunotherapy in hepatocellular carcinoma.
PMID 41555384 · PMC12895822 · Journal of translational medicine · 2026 · 8 claims · 8 setups
A parsimonious 2-gene immune-related signature (IRS = 0.425×KPNA2 + 0.302×SMG5) is significantly associated with immune heterogeneity and response to ICI plus anti-angiogenic combination therapy in HCC
-
Has reproduction · 80
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity.
PMID 36928603 · PMC10101853 · Nature genetics · 2023 · 8 claims · 6 setups
The WHO histopathological classification of MPM accounts for only up to ~10% of interpatient molecular differences